Edgar Filing: Enyedy Mark J - Form 4

Envedy Mark I

Enyedy Marl Form 4	κJ									
January 04, 2	2019									
FORM	1 /								PPROVAL	
	UNITED ST		SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549				OMB Number:	3235-0287		
Check thi if no long	ar							Expires:	January 31, 2005	
subject to Section 1	6. SIAIEME	STATEMENT OF CHANGES IN BENEFICIAI SECURITIES					NERSHIP OF	Estimated average burden hours per		
Form 4 or Form 5 obligations may continue. See Instruction 1(b). Form 5 See Instruction 1(c) See Instruction								0.5		
(Print or Type F	Responses)									
			2. Issuer Name and Ticker or Trading ymbol				5. Relationship of Reporting Person(s) to Issuer			
		IMMUN	MUNOGEN INC [IMGN]				(Check all applicable)			
(Last)	(First) (Midd		Earliest Tr	ansaction						
			(Month/Day/Year) 01/03/2019				_X_ Director 10% Owner _X_ Officer (give title Other (specify below) below) Chief Executive Officer			
			ff Amendment, Date Original ed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check			
							Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
							Person			
(City)	(State) (Zip) Tabl	e I - Non-D	erivative S	Securi	ities Aco	quired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	a	A. Deemed xecution Date, if ny Month/Day/Year)	3. Transactio Code (Instr. 8)	 4. Securities Acquired action(A) or Disposed of (D) 8) (Instr. 3, 4 and 5) 			Securities Beneficially (Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
C			Code V	Amount	(A) or (D)	Price \$	Transaction(s) (Instr. 3 and 4)			
Common Stock (1)	01/03/2019		А	2,455	А	4.08 (2)	534,838	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Enyedy Mark J - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. ofNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Secur (Instr.	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Own Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
Enyedy Mark J 24 CONCORD SQUARE BOSTON, MA 02118	Х		Chief Executive Officer					
Signatures								
/s/ David Foster, attorney in fact	01	/04/2019						
**Signature of Reporting Person		Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from July 1, 2018 through December 31, 2018.
- (2) In accordance with the ESPP; these shares were purchased based on 85% of the closing price of the issuer's common stock on December 31, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.